Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Torresi

Showing results (121-130 of 125) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 125 results.
Vaccine|August 26, 2011
Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific MeetingSai Kit Lam, Donald Burke, Maria Rosario Capeding, et al.
NPJ Vaccines|January 17, 2026
Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59Linda Earnest, Daniel Fernandez Ruiz, Melissa A Edeling, et al.
Immunity|May 5, 2021
CD8<sup>+</sup> T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuityThi H O Nguyen, Louise C Rowntree, Jan Petersen, et al.
Ebiomedicine|May 6, 2023
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineGeorgia Deliyannis, Nicholas A Gherardin, Chinn Yi Wong, et al.
Ebiomedicine|November 28, 2023
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose boosterTerry M Nolan, Georgia Deliyannis, Maryanne Griffith, et al.
Pageof 13

Showing results (121-130 of 125) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 125 results.
Vaccine|August 26, 2011
Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific MeetingSai Kit Lam, Donald Burke, Maria Rosario Capeding, et al.
NPJ Vaccines|January 17, 2026
Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59Linda Earnest, Daniel Fernandez Ruiz, Melissa A Edeling, et al.
Immunity|May 5, 2021
CD8<sup>+</sup> T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuityThi H O Nguyen, Louise C Rowntree, Jan Petersen, et al.
Ebiomedicine|May 6, 2023
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineGeorgia Deliyannis, Nicholas A Gherardin, Chinn Yi Wong, et al.
Ebiomedicine|November 28, 2023
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose boosterTerry M Nolan, Georgia Deliyannis, Maryanne Griffith, et al.
Pageof 13